Clinical Rheumatology

, Volume 11, Issue 4, pp 492–497 | Cite as

Prevention of post-menopausal bone loss with 1α-hydroxy vitamin D3 a three-year prospective study

  • J. M. Pouilles
  • F. Tremollieres
  • C. Ribot
Originals

Summary

An open and controlled prospective study was used to assess the preventive efficiency of 1α-hydroxy vitamin D3 (1α (OH) Vit. D3) on post-menopausal vertebral bone loss. Of the 36 patients included in the study, 25 completed two years of treatment with 1 μg/day of 1α (OH) Vit. D3 and 500 mg of calcium. The vertebral bone mineral density measured by dual photon absorptiometry did not vary in the treated group, whereas it decreased significantly in the control group at the end of the 2 years. At two years, withdrawal of treatment led to a signficant bone loss, whereas bone mass remained stable in a subgroup of patients who underwent a third year of treatment with 1α (OH) Vit. D3. Overall, tolerance was satisfactory. However, urinary calcium increased significantly during treatment and one third of the patients developed hypercalciuria ≥7.5 mmoles/24 h. No variation in either serum calcium or creatinine levels was noted. These results indicate that 1α (OH) Vit. D3 could be useful in preventing post-menopausal bone loss provided it was complemented by regular monitoring of urinary calcium excretion.

Key words

Osteoporosis Prevention 1α-Hydroxy Vitamin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Riggs, B.L., Melton III, J. Involutional osteoporosis. N Engl J Med 1986, 314, 1676–1686.CrossRefPubMedGoogle Scholar
  2. 2.
    Gallagher, J.C., Riggs, B.L., Eisman, J., Hamstra, A., Arnaud, S.B., Deluca, H.F., Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients. Effect of age and dietary calcium. J Clin Invest 1979, 64, 729–736.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Riggs, B.L., Nelson, K.I. Effect of long-term treatment with calcitriol on calcium absorption and mineral metabolism in post-menopausal osteoporosis. J Clin Endocrinol Metab 1985, 61, 457–461.CrossRefPubMedGoogle Scholar
  4. 4.
    Gallagher, J.C., Riggs, B.L., Action of 1,25-Dihydroxyvitamin D3 on calcium balance and bone turnover and its effects on vertebral fracture rate. Metabolism 1990, Suppl. I, 39, 30–34.CrossRefPubMedGoogle Scholar
  5. 5.
    Caniggia, A., Nuti, R., Loré, F., Martini, G., Turchetti, V., Righi, G. Pathophysiological study in women with postmenopausal osteoporosis on long-term treatment with calcitriol. In: Osteoporosis: Physiological Basis, Assessment, and Treatment, Eds: DeLuca, H.F. Mazess, R.B. 1990, 201–212.Google Scholar
  6. 6.
    Need, A.G., Nordin, C., Horowitz, M., Morris, H.A. Calcium and calcitriol therapy in osteoporotic postmenopausal women with impaired calcium absorption. Metabolism 1990, Suppl. I, 39, 53–54.CrossRefPubMedGoogle Scholar
  7. 7.
    Heaney, R.P., Recker, R.R., Stegman, M.R., Moy, A.J.J. Calcium absorption in women: relationships to calcium intake, estrogen status, and age. J Bone Min Res 1989, 4, 469–475.CrossRefGoogle Scholar
  8. 8.
    Eastell, R., Yergey, A.L., Vieira, N.E., Cedel, S.L., Kumar, R., Riggs, B.L. Interrelationship among vitamin D metabolism, true calcium absorption, parathyroid function, and age in women: evidence of an age-related intestinal resistance to 1,25-Dihydroxyvitamin D action. J Bone Min Res 1991, 6, 125–132.CrossRefGoogle Scholar
  9. 9.
    Epstein, S., Bryce, G., Hinman, J.W., Miller, O.N., Riggs, B.L., Hui, S.L., Johnston, C.C. The influence of age on bone mineral regulating hormones. Bone 1986, 7, 421–425.CrossRefPubMedGoogle Scholar
  10. 10.
    Hartwell, D., Juel Riis, B., Christiansen, C. Changes in vitamin D metabolism during natural and medical menopause. Clin Endocrinol Metab 1990, 71, 127–132.CrossRefGoogle Scholar
  11. 11.
    Falch, J.A., Oftebro, H., Haug, E. Early postmenopausal bone loss is not associated with a decrease in circulating levels of 25-hydroxy-vitamin D, 1,25-dihydroxyvitamin D, or vitamin D-binding-protein. J Clin Endocrinol Metab 1987, 64, 836–841.CrossRefPubMedGoogle Scholar
  12. 12.
    Malluche, H.H., Faugere, M.C. Role of calcitriol in the management of osteoporosis. Metabolism 1990, Suppl. I, 39, 24–26.CrossRefPubMedGoogle Scholar
  13. 13.
    Drezner, M.K., Nesbitt, T. Role of calcitriol in prevention of osteoporosis: Part I. Metabolism 1990, Suppl. 39, 180–23.Google Scholar
  14. 14.
    Geusens, P., Dequeker, J., Nijs, J., Verstraeten, A., Bramm, E. Prevention and treatment of osteopenia in the ovariectomized rat: effect of combined therapy with estrogens, 1-alpha vitamin D, and prednisolone. Calcif Tissue Int 1991, 48, 127–137.CrossRefPubMedGoogle Scholar
  15. 15.
    Pouilles, J.M., Trémollières, F., Louvet, J.P., Fournie, B., Morlock, G., Ribot, C. Sensitivity of dual-photon absorptiometry in spinal osteoporosis. Calcif Tissue Int 1988, 43, 329–334.CrossRefPubMedGoogle Scholar
  16. 16.
    Christiansen, C., Christensen, M.S., McNair, P., Hagen, C., Stocklund, K.E., Transbol, I. Prevention of early postmenopausal bone loss. Controlled 2-year study in 315 normal females. Eur J Clin Invest 1980, 10, 273–279.CrossRefPubMedGoogle Scholar
  17. 17.
    Christiansen, C., Christensen, M.S., Rodbro, P., Hagen, C., Transbol, I. Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis. Eur J Clin Invest 1981, 11, 305–309.CrossRefPubMedGoogle Scholar
  18. 18.
    Riis, B.J., Thomsen, K., Christiansen, C. Does vitamin 24R, 25 (OH)2D3 prevent postmenopausal bone loss? Calcif Tissue Int 1986, 39, 123–126.CrossRefGoogle Scholar
  19. 19.
    Sorensen, O.H., Andersen, R.B., Christensen, M.S., Friis, T., Hjorth, L., Jorgensen, F.S., Lund, B., Melsen, F., Mosekilde, L. Treatment of senile osteoporosis with 1α-hydroxyvitamin D3. Clin Endocrinol 1977, 7, Suppl., 169S-175S.CrossRefGoogle Scholar
  20. 20.
    Marshall, D.H., Nordin, B.E.C. The effect of 1α-hydroxyvitamin D3 with and without oestrogens on calcium balance in postmenopausal women. Clin Endocrinol 1977, 7, Suppl., 159s-168s.CrossRefGoogle Scholar
  21. 21.
    Hoikka, V., Alhava, E.M., Aro, A., Karjalaïnen, P., Rehnberg, V. Treatment of osteoporosis with 1-alpha-hydroxycholecalciferol and calcium. Acta Med Scand 1980, 207, 221–224.CrossRefPubMedGoogle Scholar
  22. 22.
    Lindholm, T.S., Nilsson, O.S., Kyhle, B.R., Elmstedt, E., Lindholm, T.C., Eriksson, S.A. Failures and complications in treatment of osteoporotic patients treated with 1α-hydroxyvitamin D3 supplemented by calcium. In: Osteoporosis, Eds.: Menczel J., et al. Chichester, John Wiley & Sons, 1982, 351–357.Google Scholar
  23. 23.
    Nordin, B.E.C., Horsman, A., Grilly, R.G., Marshall, D.H., Simpson, M. Treatment of spinal osteoporosis in postmenopausal women. Br Med J 1980, 280, 451–454.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Geusens, P., Dequeker, J. Long-term effect of nandrolone decanoate, 1α-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone Mineral 1986, 1, 347–357.PubMedGoogle Scholar
  25. 25.
    Orimo, H., Shiraki, M., Hayashi, T., Nakamura, T. Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1α-hydroxyvitamin D3 Bone Mineral 1987, 3, 47–52.PubMedGoogle Scholar
  26. 26.
    Fujita, T. Studies of osteoporosis in Japan. Metabolism 1990, 4, Suppl. 1, 39–42.CrossRefGoogle Scholar
  27. 27.
    Aloia, J.F., Vaswani, A., Yeh, J., Ellis, K., Yasumura, S., Cohn, S. Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 1988, 84, 401–408.CrossRefPubMedGoogle Scholar
  28. 28.
    Gallagher, J.C., Godgar, D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitritiol. A randomized controlled study. Ann Int Med 1990, 113, 649–655.CrossRefPubMedGoogle Scholar
  29. 29.
    Geusens, P., Vanderschueren, D., Verstraeten, A., Dequeker, J., Devos, P., Bouillon, R. Short-term course of 1,25 (OH)2D3 stimulates osteoblasts but not osteoclasts in osteoporosis and osteoarthritis. Calcif Tissue Int 1991, 49, 168–173.CrossRefPubMedGoogle Scholar
  30. 30.
    Ott, S.M., Chesnut, C.H. Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Int Med 1989, 110, 267–274.CrossRefPubMedGoogle Scholar
  31. 31.
    Ott, S.M., Chesnut, C.H. Tolerance to dose of calcitriol is associated with improved bone density in women with postmenopausal osteoporosis. J Bone Min Res 1990, Suppl. 2, S186.Google Scholar
  32. 32.
    Raisz, L.G. Direct effects of vitamin D and its metabolites on skeletal tissue. Clin Endocrinol Metab 1980, 9, 27–33.CrossRefPubMedGoogle Scholar
  33. 33.
    Lund, B., Sorensen, O.H., Lund, B.J. 1α-hydroxycholecalciferol and renal function. Lancet ii 1978, 731.CrossRefGoogle Scholar
  34. 34.
    Verstraeten, A., Dequeker, J., Nijs, J., Geusens, P. Prevention of postmenopausal bone loss in rheumatoid arthritis patients. A two-year prospective study. Clin Exp Rheumatol 1989, 7, 351–358.PubMedGoogle Scholar

Copyright information

© Acta Medica Belgica 1992

Authors and Affiliations

  • J. M. Pouilles
    • 1
  • F. Tremollieres
    • 1
  • C. Ribot
    • 1
  1. 1.Service d'Endocrinologie- U.F.Maladies Osseuses et Métaboliques-CHU PurpanToulouse CedexFrance

Personalised recommendations